June 2009 clinical trials update
By Jim Hughes
LRG Clinical Trials Coordinator
BKM120 Phase 1: A new Novartis PI3K inhibitor, BMK120, is now recruiting at Sarah Cannon in Nashville, Tenn. As with most Phase 1 trials, this trial is for “Solid Tumors” which should include GIST. BMK120 inhibits PI3K but unlike the other Novartis PI3K inhibitors, BEZ235 and BGT226, it does not also inhibit mTOR.
Nilotinib Versus Imatinib: 15 new sites are listed as recruiting in Austria, Brazil, Canada and Japan
